The introduction of newborn screening for spinal muscular atrophy (SMA) in parts of the UK is being positioned as a breakthrough moment. While it does represent progress, the reality is far less encouraging. When examined closely, the scale and pace of implementation raise serious concerns about whether this approach truly meets the needs of families affected by this devastating condition.
A Limited Rollout Leaves Thousands Behind
Scotland’s decision to begin screening all newborns for SMA means approximately 45,000 babies a year will be tested.
At first glance, this appears significant. But in the context of the wider UK, it highlights a glaring disparity.
The UK sees hundreds of thousands of births annually, yet screening is not being implemented nationwide. Instead, progress is fragmented, with only certain regions or pilot programmes in place. This effectively creates a postcode lottery, where a child’s chance of early diagnosis depends on where they are born.
Even more concerning is that planned research programmes and pilot schemes will only cover a proportion of the population, with some estimates suggesting around 60% coverage due to laboratory limitations.
That means tens of thousands of babies could still miss out on early detection every year.
Delays That Continue to Cost Lives
The UK has already spent years debating whether to introduce SMA screening. Back in 2018, the UK National Screening Committee chose not to include SMA in the newborn screening programme, citing insufficient evidence.
Since then, other countries have moved ahead decisively, implementing nationwide screening and demonstrating clear benefits. Meanwhile, the UK continues to rely on slow-moving pilots and evaluations.
This delay has real consequences. Without screening, babies are often only diagnosed after symptoms appear, by which point irreversible damage has already occurred. Evidence consistently shows that early diagnosis dramatically improves outcomes, yet the system still fails to deliver this universally.
A Positive Step, But Not a Solution
It would be wrong to dismiss the introduction of screening entirely. For the babies who are tested, it could be life-changing. Early access to treatment can significantly improve mobility, development, and overall quality of life.
However, focusing on the positive risks masking a deeper issue: the current approach is far too limited to be considered a true solution.
Screening a fraction of newborns or rolling out programmes slowly over several years does not match the urgency of the condition. SMA progresses rapidly, often before symptoms are visible. Every delay, every missed diagnosis, represents a lost opportunity to intervene early.
There will be literally families miles apart where one baby will be screened and another won't. It's just another postcode lottery forced upon the lives of disabled people that we are supposed to be grateful for, but it simply isn't good enough. Especially when it comes to the life of a child.
The Bigger Picture: A System Falling Behind
The UK’s newborn screening programme currently tests for just nine conditions, far fewer than many comparable countries.
This broader context highlights a systemic issue: the UK is lagging behind in adopting modern, evidence-based screening practices.
Campaigners and clinicians, such as Neurologist Laurent Servais
have repeatedly called for faster action, pointing out that early diagnosis is not just beneficial but essential. Families who have lost their babies have written to MPS for decades, begging for change. Yet progress remains slow, constrained by bureaucracy, funding challenges, and an over-reliance on further evidence gathering.
What Needs to Happen Next
If the UK is serious about improving outcomes for children with SMA, incremental change will not be enough. What is needed is:
* Nationwide implementation, not regional pilots
* Full population coverage, not partial or limited rollouts
* Urgent timelines, not multi-year evaluations
* A commitment to equity, ensuring every baby has the same chance at early diagnosis
Until these steps are taken, the current progress risks are being seen not as a breakthrough but as a missed opportunity.
Conclusion
Introducing newborn screening for SMA is undeniably a step in the right direction. But it is a small step, and one that falls far short of what is required.
For families affected by SMA, the difference between early and late diagnosis can be life-altering. Limiting screening to a subset of babies or delaying nationwide adoption means that many will continue to face preventable harm.
The UK now stands at a crossroads: build on this progress with urgency and ambition, or continue with a piecemeal approach that leaves too many children behind.